Drug companion protocol
Retatrutide
A triple receptor agonist (GLP-1, GIP, glucagon) in late-stage clinical development for obesity and metabolic disease.
Quickstart Highlights
- Drug class
- GLP-1 / GIP / glucagon triple receptor agonist
- Route
- Subcutaneous injection
- Schedule
- Once-weekly subcutaneous injection, titrated over 12β26 weeks from a starting dose of 2 mg/week
- Evidence score
- 55
Quickstart highlights
- πSubcutaneous injection
- π¬GLP-1 / GIP / glucagon triple receptor agonist
- π§ͺLyophilised powder β requires reconstitution with bacteriostatic water
- πPrescription required
How this works
Mechanism of action and pharmacokinetic profile from published data.
Retatrutide is a novel triple receptor agonist that activates the glucagon, GIP (glucose-dependent insulinotropic polypeptide), and GLP-1 (glucagon-like peptide-1) receptors with balanced potency. The glucagon component is thought to increase energy expenditure; GIP and GLP-1 agonism improves insulin secretion, slows gastric emptying, and reduces appetite. Phase 2 data suggest weight-loss effects that exceed those reported for single- or dual-receptor agonists, though longer-term safety and efficacy are still being studied in Phase 3 trials.
- Time to peak (Tmax)
- 24β72 hours after a subcutaneous injection.
- Clearance
- Catabolised to small peptides and amino acids via proteolytic degradation; not primarily renally or hepatically cleared as intact drug.
- Elimination half-life
- Approximately 6 days in humans, which supports once-weekly subcutaneous dosing.
- Bioavailability
- High systemic exposure after subcutaneous injection; retatrutide is a peptide and is not orally bioavailable.
Dosing & Reconstitution Guide
Full preparation, protocol, and administration reference for compounded lyophilised formulations.
Protocol overview
Once-weekly subcutaneous injection, titrated over 12β26 weeks from a starting dose of 2 mg/week. Most compounding pharmacies dispense 10 mg or 20 mg lyophilised vials; both yield a 10 mg/mL solution when reconstituted per the guide below. Dose escalation follows a prescriber-led schedule β the Phase 2 trial used 4-week intervals before each increase. The 12 mg/week arm produced a mean 24.2 % body-weight reduction at 48 weeks in the primary obesity trial.
Supplies needed
- β¦Prescribed retatrutide lyophilised vials β Your compounding pharmacy will dispense the vial size and quantity prescribed. Check the label matches your prescription.
- β¦Bacteriostatic water for injection (10 mL vials) β Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is used as the reconstitution diluent. Sterile water for injection is an alternative but offers no bacteriostatic protection; use reconstituted solution within 24 hours if sterile water is used.
- β¦U-100 insulin syringes (1 mL) β Use 1 mL U-100 syringes β they are calibrated in 1-unit increments (1 unit = 0.01 mL). Common needle sizes: 29Gβ31G Γ 5β8 mm. Use one syringe per injection; never reuse.
- β¦Alcohol swabs β To wipe the vial rubber stopper and injection site before each use.
- β¦Labels and a fine-tip marker β Label each vial with the reconstitution date and concentration so you can track the 4-week use window.
- β¦Sharps disposal container β A rigid, puncture-resistant container for used syringes and vial caps.
Dosing Protocol
Quick reference for converting your prescribed dose to syringe units and injection volume at 10 mg/mL concentration.
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| 2 mg | 20 | 0.20 |
| 4 mg | 40 | 0.40 |
| 6 mg | 60 | 0.60 |
| 8 mg | 80 | 0.80 |
| 10 mg | 100 | 1.00 |
| 12 mg | 120 | 1.20 |
Standard / Gradual Approach
Conservative titration schedule matching the primary Phase 2 protocol. The recommended starting point for most patients.
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| Weeks 1β4 | 20 | 0.20 |
| Weeks 5β8 | 40 | 0.40 |
| Weeks 9β12 | 60 | 0.60 |
| Weeks 13+ | 80 | 0.80 |
Advanced Aggressive Protocol
Higher-dose arm from Phase 2, used for participants who tolerated the standard schedule well. Reach the 12 mg target dose sooner.
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| Weeks 1β4 | 20 | 0.20 |
| Weeks 5β8 | 40 | 0.40 |
| Weeks 9β12 | 80 | 0.80 |
| Weeks 13+ | 120 | 1.20 |
Reconstitution steps
Vial size
10 mg
BAC water to add
1 mL
Resulting concentration
10 mg/mL
At 10 mg/mL: on a U-100 insulin syringe, 1 unit = 0.01 mL = 0.1 mg of retatrutide.
Allow the vial to reach room temperature before opening β this reduces condensation inside the vial. Remove the protective cap from the vial. Wipe the rubber stopper with an alcohol swab and allow to dry. Draw 1.0 mL of bacteriostatic water into an insulin syringe. Insert the needle through the rubber stopper and inject the water slowly down the inner wall of the vial β do not squirt it directly onto the powder. Gently swirl or roll the vial between your palms until the powder is fully dissolved. Do not shake β shaking can degrade the peptide. Hold the vial up to the light and inspect: the solution should be clear and colourless. A very faint yellow tinge is sometimes normal for retatrutide but discard if cloudy, visibly particulate, or strongly discoloured. Label the vial with the reconstitution date and concentration (10 mg/mL). Refrigerate immediately.
Vial size
20 mg
BAC water to add
2 mL
Resulting concentration
10 mg/mL
At 10 mg/mL: on a U-100 insulin syringe, 1 unit = 0.01 mL = 0.1 mg of retatrutide.
Allow the vial to reach room temperature before opening. Wipe the rubber stopper with an alcohol swab and allow to dry. Draw 2.0 mL of bacteriostatic water. Inject slowly down the inner vial wall β do not squirt directly onto the powder. Gently swirl or roll until fully dissolved. Do not shake. Inspect: solution should be clear and colourless. Discard if cloudy or particulate. Label with reconstitution date and concentration (10 mg/mL). Refrigerate immediately. For extended storage: the reconstituted solution may be aliquoted into smaller volumes using sterile technique and frozen at β20 Β°C. Thaw each aliquot once only β do not refreeze.
Injection steps
- 1Wash your hands thoroughly
- 2Set up a clean workspace
Use a clean, flat surface. Lay out your supplies. Do not work near an open window or fan.
- 3Draw up your dose
Wipe the vial rubber stopper with a fresh alcohol swab. Allow to dry. Draw back the syringe plunger to your target volume to fill with air, then inject air into the vial (inverted) before drawing the solution β this makes extraction easier. Pull back the plunger to draw the exact volume for your prescribed dose. Refer to the concentration reference table above for the mL volume for your dose.
- 4Remove air bubbles
Hold the syringe needle-up, tap to bring bubbles to the top, and gently press the plunger to expel air. Recheck that the volume is correct.
- 5Choose and clean your injection site
Rotate between the abdomen (at least 5 cm from the navel), front of the upper thigh, and upper arm. Wipe with an alcohol swab and allow to dry completely before injecting.
- 6Inject subcutaneously
Pinch a skinfold if you have a thin subcutaneous layer. Insert the needle at 45β90Β° into the fatty tissue. Do not aspirate for subcutaneous injections. Inject slowly and steadily. Wait 3β5 seconds before withdrawing.
- 7Withdraw and apply gentle pressure
Withdraw the needle smoothly. Apply light pressure with a clean swab β do not rub. A small bleed or bruise is normal.
- 8For doses above 1.0 mL, split the injection
Volumes greater than 1.0 mL should be split across two injection sites at different locations to reduce discomfort and local absorption issues.
- 9Dispose and return vial to fridge
Place the used syringe directly into your sharps container. Return the reconstituted vial to the refrigerator (2β8 Β°C). Record the injection date, site, and dose.
Storage instructions
Before reconstitution
Store unopened lyophilised vials at β20 Β°C (β4 Β°F) or colder. Stable for up to 24 months when stored correctly. Allow to reach room temperature before reconstituting.
After reconstitution
Refrigerate at 2β8 Β°C (35β46 Β°F). Protect from light (keep in the original carton or a drawer).
Use within 4 weeks of reconstitution.
Important notes
- !Your prescriber determines your dose and escalation β not this guide
The dose reference tables on this page are drawn from published Phase 2 trial protocols. Your actual prescribed dose, escalation schedule, and target may differ. Always follow your prescriber's instructions.
- !Never inject into a vein or muscle
Retatrutide is a subcutaneous injection only. Intravenous or intramuscular injection changes absorption kinetics and can cause serious reactions.
- !Rotate injection sites every week
Injecting the same spot repeatedly causes lipohypertrophy β a hardened lump that impairs absorption unpredictably.
- !Do not shake the reconstituted vial
Shaking can cause foaming and peptide degradation. Swirl or roll gently only.
- !Discard reconstituted vial after 4 weeks
Even refrigerated, reconstituted peptide degrades over time and bacteriostatic protection is not indefinite. Label every vial with the reconstitution date.
- !Do not use if solution is cloudy or has particles
These are signs of degradation or contamination. Discard the vial and contact your pharmacy.
- !Compounded retatrutide is not TGA-approved
Retatrutide has not been approved by the TGA, FDA, or EMA. Compounded versions dispensed by Australian compounding pharmacies operate under different regulatory pathways. Discuss this with your prescriber.
- !Tell all healthcare providers you are using retatrutide
Slowed gastric emptying affects fasting preparation for procedures and absorption of other oral medicines.
Sharps disposal
- β¦Place all used syringes in a sharps container immediately after use β Do not recap needles with two hands β use the one-hand scoop technique if recapping is necessary.
- β¦NestSafe sharps mail-back program (Australia) β Free household sharps mail-back. Collect a kit from participating pharmacies or via nestsafe.com.au.
- β¦EnviroSafe sharps mail-back (Australia) β Available from participating pharmacies at no cost to patients.
- β¦Community pharmacy drop-off β Many Australian pharmacies accept full sharps containers. Ask your dispensing pharmacy.
- β¦Vial disposal β Empty glass vials can be placed in a sharps container or returned to your compounding pharmacy if they offer a take-back service.
Concentration calculations are standard compounding arithmetic. Protocol phases are drawn from published Phase 2 trial data. Your prescriber and dispensing pharmacy determine the actual dose, vial size, and escalation schedule for your treatment.
Clinical Benefits & Side Effects
Observed outcomes, adverse effects, and lifecycle considerations from published trial data.
Benefits
Starting treatment
Trials began at a low dose (typically 2 mg weekly subcutaneously) and escalated in steps over several weeks. Expect a prescriber-led titration schedule rather than starting at a target dose.
First injection β taking the first step
You've done it β your first injection is behind you. This week is about getting familiar with the process and listening to your body. You may feel completely normal, or you might notice mild nausea, a reduced appetite, or some fatigue β all of these are common early signs that the medication is working.
Body beginning to notice the change
Side effects like nausea, bloating, or a feeling of fullness after small meals may become a little more noticeable this week. These sensations are your body adjusting to retatrutide's effects on multiple gut and metabolic receptors. Try not to be discouraged β most people find these symptoms manageable with the right eating habits and hydration.
Finding your post-injection rhythm
By now you may be identifying patterns β perhaps nausea peaks a day or two after your injection and then settles. Use this knowledge to plan lighter meals and gentler activities around your injection day. Weight change at this stage is unlikely to be dramatic, and that's completely normal.
Completing your first month β well done
You've reached the end of your first month, and that is genuinely worth acknowledging. Your dose is still in its early phase, so visible results on the scale may be modest or not yet present β and that's okay. Focus on building consistent habits around food, hydration, and sleep this week rather than the number on the scales.
Early GI adjustment
Across Phase 2 trials, nausea, mild diarrhoea, or reduced appetite most often appeared in the first 4β8 weeks while the dose was escalating, then eased with continued use. Slow-paced eating and good hydration helped many participants.
Dose may increase β appetite shifts ahead
If your prescriber has scheduled a dose escalation, you may notice stronger appetite suppression over the coming days β follow your prescriber's instructions carefully regarding any dose changes. Some people experience a return of nausea as the dose adjusts upward; the strategies that helped in weeks 1β4 will serve you well again here.
Appetite suppression becoming more noticeable
Many people start to feel a meaningful reduction in hunger and food 'noise' β that constant background thinking about food β around this week. It can feel quite unfamiliar to feel satisfied with a smaller plate. Try to honour your body's new hunger signals without undereating to the point of dizziness or fatigue.
Side effects
Small average increases observed across dose arms
~15β20%
Reported; less frequent than some other GLP-1 family agents
Frequently reported β often an intended effect of the medicine
~25β30%
Reported; dose-related
Reported; dose-related
~35β50% at 12 mg; most common during titration
Lifecycle factors
Keep a brief symptom log
A few lines per day covering nausea, appetite, bowel habits, and any dizziness gives your prescriber real information to titrate against. Trial participants who tracked symptoms had a better conversation at their next visit.
Manage nausea with the BRAT-style approach
On days when nausea is significant, reach for bland, easily digestible foods β plain crackers, dry toast, steamed rice, or a mild broth. Cold or room-temperature foods are often better tolerated than hot meals when your stomach is unsettled. Ginger tea or ginger chews are a practical, evidence-informed option worth keeping in the pantry. If nausea is severe or persistent, always let your prescriber know β don't just push through.
Early GI symptoms are usually transient
In Phase 2, most nausea and GI symptoms were mild to moderate and occurred during the first 4β8 weeks of titration. They generally improved with continued use β but if they are severe or persistent, contact your prescriber.
Weight may return after stopping
Retatrutide suppresses appetite by activating receptors that control hunger and energy expenditure β effects that subside once the drug clears. With a half-life of ~6 days, retatrutide takes roughly 5β6 half-lives (30β36 days) to be almost entirely eliminated. Without a transition plan, most people regain a portion of lost weight over the following months. Talk with your prescriber before stopping β some patients transition to a lower maintenance dose (2β4 mg/week) rather than stopping abruptly.
Allow enough time for meaningful results
Phase 2 trials ran for 36β48 weeks, and most participants reached their lowest weight between weeks 24 and 48. Starting a course with a short-term mindset (under 12 weeks) is unlikely to produce sustained results β the dose is still escalating during that window and weight loss typically accelerates after week 12.
Important note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is not TGA/FDA-approved and is available only for research purposes. All information presented is based on published clinical trial data and is not intended to encourage off-label use.
Nutrition & practical guidance
Food, hydration, and adherence tips compiled from trial data and clinical companion content.
Food and hydration
β Prefer
β οΈ Limit
Adherence tips
Rotate your injection sites consistently
Retatrutide is given as a weekly subcutaneous injection into the abdomen, outer thigh, or upper arm β follow your prescriber's instructions on technique. Rotating your injection site each week (e.g. left abdomen β right abdomen β left thigh) helps prevent skin irritation, lumps, or hardening at the injection site. Keep a simple log or diagram to track where your last injection was. If you notice unusual redness, swelling, or pain at any site, let your prescriber know.
Let the pen reach room temperature before injecting
Injecting medication straight from the fridge can cause stinging and discomfort at the injection site. Take your pen or syringe out of the fridge 20β30 minutes before your scheduled injection time and leave it on a clean surface away from direct sunlight. Do not warm it in hot water or a microwave β room temperature is all that's needed. This simple step can make your weekly injection noticeably more comfortable.
Eat slowly and stop earlier than you think you need to
Slowed gastric emptying means your satiety signal arrives later. Putting down the fork every few bites and pausing gives your brain time to catch up β most participants who tolerate the medicine well found their portions shrank gradually rather than all at once.
Do not self-adjust your dose
Phase 2 trials used a prescriber-led titration. Skipping doses to ease side effects, or jumping ahead to a higher dose, both increased adverse events in the trial data. Talk with your prescriber before changing anything.
Pick a consistent injection day and stick to it
Choosing the same day each week β say, every Sunday morning β helps build the habit and makes it easier to plan around any side effects. Many people choose a day when they have a lighter schedule the following day, in case nausea is present. Set a phone reminder if it helps. Always follow your prescriber's instructions if your scheduled day needs to change.
Sip water steadily β don't gulp large amounts
Drinking a large glass of water quickly can trigger or worsen nausea, especially in the early weeks. Instead, aim to sip water consistently throughout the day β small amounts, often. A 600 mL bottle at your desk or on your bench is a great visual reminder. Herbal teas like ginger or peppermint count toward your daily intake and may also settle an uneasy stomach.
Pick a consistent injection day
A weekly medicine is easier to remember when it is tied to the same day each week. If you miss a dose, there are published rules for how long after the scheduled day you can still take it β your prescriber or trial site will provide them.
Eat protein first at every meal
With a reduced appetite, every bite needs to work hard for you. Make protein the first thing you reach for β a few bites of chicken, some cottage cheese, eggs, or legumes β before moving to other parts of the meal. This helps ensure you're hitting your protein targets even on low-appetite days. A general guide is aiming for around 1.2β1.6 g of protein per kilogram of your body weight daily, but speak with your prescriber or a dietitian for personalised guidance.
Prioritise protein intake during weight loss
Aiming for roughly 1.2β1.6 g of protein per kg of body weight daily helps preserve lean mass while you lose fat. If your appetite is small, protein-first plating (protein before carbs or vegetables) helps.
Eat small portions slowly β and stop when satisfied
Retatrutide slows how quickly food leaves your stomach, which means fullness can arrive faster and more intensely than you're used to. Serve yourself smaller portions than you think you need, eat slowly, and pause between bites. Stopping at 'satisfied' rather than 'full' will help you avoid uncomfortable nausea and bloating after meals. Using a smaller plate can be a surprisingly effective way to recalibrate portion size.
Start with short walks and build gradually
You don't need to join a gym or run 5 km to support your progress β a 15β20 minute walk after dinner is a genuinely meaningful starting point. Movement helps with digestion, mood, and maintaining muscle mass during weight loss. As your energy improves over the coming weeks, aim to increase duration or add a second walk per day. Apps like Google Maps can help you measure distances in kilometres if you'd like to track your walks.
Include resistance training to protect muscle
When the body loses weight, it can lose muscle alongside fat β resistance training (bodyweight exercises, resistance bands, or weights) helps minimise this. You don't need to be experienced; simple exercises like squats, wall push-ups, and step-ups are a great beginning. Aim for two sessions per week and build from there. If you're new to exercise, a single session with an exercise physiologist can set you up with a safe, personalised routine.
Prioritise 7β9 hours of quality sleep each night
Sleep plays a direct role in appetite regulation, energy, and metabolic health β poor sleep can increase hunger hormones and undermine your progress. Try to keep a consistent bedtime and wake-up time, even on weekends. Avoid screens for 30β60 minutes before bed and keep your bedroom cool and dark. If sleep has been a long-standing challenge, it's worth raising with your prescriber as part of your overall health plan.
Measure progress beyond the scales
The number on the scales tells only part of the story β and in the early weeks, it may not move much at all. Track other meaningful markers: how your clothes fit, your energy levels throughout the day, how far you can walk, your sleep quality, and how you feel about your food choices. Consider keeping a brief weekly journal β even three or four sentences β to capture these non-scale wins. Progress is rarely linear, and the full picture is worth seeing.
Be kind to yourself on the hard days
Some weeks will feel harder than others β nausea, fatigue, slow progress, or simply life getting in the way. These are normal parts of the journey, not signs of failure. Reaching out to a friend, a support community, or a health professional on tough days is a sign of strength, not weakness. Remember: you are doing something meaningful for your long-term health, and every week you show up counts.
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Who should not take this
Retatrutide is investigational and has not been approved by the TGA, FDA, MHRA, or EMA β access is currently limited to clinical trials. Phase 2 trial protocols excluded participants with: β’ Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) β’ Severe gastrointestinal disease including gastroparesis β’ A history of pancreatitis β’ Active or recent eating disorder β’ Type 1 diabetes β’ Pregnancy or breastfeeding β’ Significant cardiovascular events in the prior 3 months Talk with your prescriber about whether any of these apply to you.
Known interactions
- Insulin and sulfonylureassignificant
Increased risk of hypoglycaemia when combined with agents that stimulate insulin secretion or deliver exogenous insulin. Prescribers typically reduce insulin or sulfonylurea doses when initiating or escalating retatrutide.
- Oral medicines with a narrow therapeutic indexmoderate
Retatrutide delays gastric emptying, which can alter the absorption rate of some orally administered medicines. Particular care is warranted for drugs such as warfarin and certain anti-epileptics.
- Oral contraceptivesmoderate
Delayed gastric emptying may transiently affect oral contraceptive absorption during dose escalation. Consider additional non-hormonal contraception around dose changes β discuss with your prescriber.
- Alcoholmoderate
Alcohol can worsen nausea, dehydration, and the risk of hypoglycaemia when combined with GLP-1 family agents. Moderation is advised.
Research evidence
Published studies connected to this peptide with dosage and outcomes context.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo-and-active-controlled, parallel-group, phase 2 trial
Human trial Β· 2023 Β· The Lancet Β· n=281 Β· Adults with type 2 diabetes, HbA1c 7.0β10.5%, on diet/exercise or stable metformin
281 adults with type 2 diabetes were randomised to retatrutide (0.5, 4, 8, or 12 mg weekly subcutaneously, with titration), dulaglutide 1.5 mg weekly, or placebo, and followed for 36 weeks. HbA1c reductions were dose-dependent, reaching β2.02% at 12 mg retatrutide. Mean body-weight changes at week 36 ranged from β3.19% at 0.5 mg to β16.94% at 12 mg.
Reported outcomes
- comparator: Retatrutide 8 mg and 12 mg produced larger HbA1c and weight reductions than dulaglutide 1.5 mg weekly. (Secondary)
- weight_loss: Mean body-weight reduction of 16.94% at 12 mg weekly retatrutide at 36 weeks in type 2 diabetes. (Secondary)
- hba1c_reduction: HbA1c reduction of up to β2.02% at 12 mg weekly retatrutide over 36 weeks in adults with type 2 diabetes. (Primary efficacy outcome)
Reported dosage
- 8 mg Β· once weekly subcutaneous Β· 36 weeks β Higher dose arm; scheduled titration.
- 12 mg Β· once weekly subcutaneous Β· 36 weeks β Highest dose arm in the T2D Phase 2.
- 4 mg Β· once weekly subcutaneous Β· 36 weeks β Mid dose arm; scheduled titration.
- 0.5 mg Β· once weekly subcutaneous Β· 36 weeks β Lowest dose arm in the T2D Phase 2.
TripleβHormone-Receptor Agonist Retatrutide for Obesity β a Phase 2 Trial
Human trial Β· 2023 Β· New England Journal of Medicine Β· n=338 Β· Adults with obesity (BMI β₯30) or overweight (BMI β₯27) with at least one weight-related condition, without diabetes
338 adults were randomised to placebo or retatrutide at 1, 4, 8, or 12 mg once-weekly subcutaneously (with lower starting doses and scheduled escalation), and followed for 48 weeks. At week 48, least-squares mean percent change in body weight was β24.2% in the 12 mg group versus β2.1% with placebo. Most adverse events were gastrointestinal and mild-to-moderate.
Reported outcomes
- cardiometabolic: Favourable changes in HbA1c, lipids, and systolic blood pressure were reported across dose arms. (Secondary)
- weight_loss: Mean body-weight reduction of 24.2% at 48 weeks on 12 mg weekly retatrutide, vs 2.1% on placebo. (Primary efficacy outcome)
- weight_loss: Dose-response was observed across 1, 4, 8, and 12 mg arms with no apparent plateau at 48 weeks. (Secondary)
Reported dosage
- 8 mg Β· once weekly subcutaneous Β· 48 weeks β Higher dose arm; scheduled titration with checkpoints at 2, 4, and 6 mg.
- 12 mg Β· once weekly subcutaneous Β· 48 weeks β Highest dose arm in the trial; titration continued through 2, 4, 6, and 9 mg before reaching 12 mg.
- 1 mg Β· once weekly subcutaneous Β· 48 weeks β Lowest dose arm; all participants started at 2 mg for 4 weeks before down- or up-titration.
- 4 mg Β· once weekly subcutaneous Β· 48 weeks β Mid dose arm; scheduled titration up from 2 mg.
Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.